Xu Yong-jian, Yang Qin-he, Han Li, Zhang Yu-pei, Liu Yi-zhen, Jin Ling, Yan Hai-zhen
Zhong Yao Cai. 2014 Jan;37(1):80-6.
To observe the effects of soothing liver and invigorating spleen recipes on the expression levels of SREBP-1c, SCD-1 mRNA and proteins in hepatocytes of NAFLD rats,and to explore its possible mechanisms of prevention and treatment of NAFLD.
75 SD male rats were randomly divided into 5 groups: normal group, model group, oothing liver group (administrated with 9.6 g/kg), invigorating spleen group (administrated with 30 g/kg)and integrated group (administrated with 39.6 g/kg). The rats of NASH model were induced by feeding a high-fat diet. After treatment for 8 weeks,9 rats were randomly taken to detect liver function, TC, TG and pathological changes in liver tissue. The other 6 rats of each group were taken respectively and collagenase (Type IV) was perfused to digest liver tissue with the circulation in vitro to separate hepatocytes. Real-time Q-PCR and Western Blot were used to detect the expression levels of SREBP-1c, SCD-1 mRNA and proteins.
Compared with the model group,the different decrease levels of SREBP-1c, SCD-1 genes and proteins were found in all drug therapy groups (P < 0.05 or P < 0.01), as well different degrees that liver lipid and pathological changes became better, especially that of in soothing liver group. Comparison between the all drug therapy groups,the hepatocytes expression levels of SREBP-1c and SCD-1 mRNA in soothing liver group were lower than that of in invigorating spleen group (P < 0.05), but expression levels of the proteins had no statistical significances.
Soothing liver and invigorating spleen recipes prevent and treat NAFLD,its mechanism may be related to inhibiting the activation of SREBP-1c/SCD-1 signal pathway in hepatocytes to down-regulate TC and TG synthesis and reduce hepatic lipid deposition. SREBP-1c, SCD-1 mRNA and proteins may be the effective targets.
观察疏肝健脾方对非酒精性脂肪性肝病(NAFLD)大鼠肝细胞中SREBP-1c、SCD-1 mRNA及蛋白表达水平的影响,探讨其防治NAFLD的可能机制。
将75只雄性SD大鼠随机分为5组:正常组、模型组、疏肝组(给予9.6 g/kg药物)、健脾组(给予30 g/kg药物)和综合组(给予39.6 g/kg药物)。采用高脂饮食诱导大鼠建立NASH模型。治疗8周后,随机取9只大鼠检测肝功能、总胆固醇(TC)、甘油三酯(TG)及肝组织病理变化。每组另取6只大鼠,分别用IV型胶原酶灌注消化肝组织并进行体外循环以分离肝细胞。采用实时荧光定量聚合酶链反应(Real-time Q-PCR)和蛋白质免疫印迹法(Western Blot)检测SREBP-1c、SCD-1 mRNA及蛋白表达水平。
与模型组比较,各药物治疗组SREBP-1c、SCD-1基因及蛋白表达水平均有不同程度降低(P<0.05或P<0.01),肝脂质及病理变化均有不同程度改善,尤以疏肝组明显。各药物治疗组比较,疏肝组肝细胞SREBP-1c、SCD-1 mRNA表达水平低于健脾组(P<0.05),但蛋白表达水平差异无统计学意义。
疏肝健脾方可防治NAFLD,其机制可能与抑制肝细胞中SREBP-1c/SCD-1信号通路的激活,下调TC和TG合成,减少肝脏脂质沉积有关。SREBP-1c、SCD-1 mRNA及蛋白可能是其有效的作用靶点。